Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why SNY stock is a strong buy.

Digitization has allowed Sanofi to optimize manufacturing and automate document preparation. And now, the firm predicts that ...

Chronic spontaneous urticaria places a heavier burden on patients than atopic dermatitis and psoriasis, leading to a worse ...

Apogee Therapeutics has shared positive 16-week results from a mid-stage study of its investigational anti-IL-13 antibody in ...